Clinical Trials Logo

TSC2 clinical trials

View clinical trials related to TSC2.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT03817515 Approved for marketing - TSC1 Clinical Trials

Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

Start date: n/a
Phase:
Study type: Expanded Access

Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a Malignancy with Relevant Genetic Mutations or mTOR Pathway Activation